Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 36 Neoplasms 8 Lung Neoplasms 7 Neoplasm Metastasis 4 Neoplasms by Site 3 Lymphoma, Large-Cell, Anaplastic 3 Hematologic Neoplasms 3 Breast Neoplasms 3 Brain Neoplasms 3 Thyroid Neoplasms 2 Sarcoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Histologic Type 2 Lymphoproliferative Disorders 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Urinary Bladder Neoplasms 1 Thyroid Cancer, Papillary 1 Thoracic Neoplasms 1 Solid Tumors 1 Sexual Dysfunction, Physiological 1 Salivary Gland Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Neuroendocrine Tumors 1

Interventions

Carboplatin 19 Pemetrexed 10 Paclitaxel 7 pembrolizumab 5 Nivolumab 5 Cisplatin 5 Gemcitabine 4 osimertinib 3 entinostat 3 camrelizumab 3 atezolizumab 3 Erlotinib Hydrochloride 3 Bronchoscopy 3 zipalertinib 2 selpercatinib 2 pralsetinib 2 durvalumab 2 apatinib 2 Vinorelbine 2 Surveys and Questionnaires 2 One-Lung Ventilation 2 Ipilimumab 2 Drug Delivery Systems 2 Docetaxel 2 Blood Specimen Collection 2 Bevacizumab 2 130-nm albumin-bound paclitaxel 2 zimberelimab 1 toripalimab 1 taletrectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Diseases × alectinib × Clear all

NCT06765109 2026-06-02

ALKAZAR

Nuvalent Inc.

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡